Actavis to pay $202M in Medicaid overbilling settlements

Actavis has agreed to pay $118 million to settle claims that the U.S. government and four states overpaid for its drugs. The deal follows an $84 million settlement of similar claims filed by the state of Texas. Report

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.